UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/761,569	01/16/2001	Roger J. Davis	10363-003004 / UMMC Ref.:	9227

26161 7590 01/29/2004

FISH & RICHARDSON PC
225 FRANKLIN ST
BOSTON, MA 02110

EXAMINER	
GAMBEL, PHILLIP	

ART UNIT	PAPER NUMBER
1644	

DATE MAILED: 01/29/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/761,569	DAVIS ET AL.	
	Examiner	Art Unit	
	Phillip Gambel	1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *02 October 2003 and 20 January 2004*.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *51-74* is/are pending in the application.

4a) Of the above claim(s) *51-64 and 66-74* is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *65* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

13)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

a) ☐ The translation of the foreign language provisional application has been received.

14)☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.
4) ☒ Interview Summary (PTO-413) Paper No(s). _____.
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other:

DETAILED ACTION

1. Applicant's election without traverse of Group I (claim 65) drawn to a method treating an MKK-mediated disorder in a patient with an antibody that binds MKK3 (SEQ ID NO: 2) in the Responses, filed 5/12/03 and reiterated 10/02/03, is acknowledged.

Upon inquiry as to the election of an MKK-mediated disorder as set forth in the Office Action, mailed 8/27/03; applicant's election of inflammation and rheumatoid arthritis as the MKK-mediated disorder is acknowledged. See attached Interview Summary of 1/20/04.

Claims 65 is being acted upon as the elected invention.

Claims 1-50 have been canceled previously.

Claims 51-64 and 66-74 have been withdrawn from from consideration by the examiner 37 CFR 1.142(b), as being drawn to a nonelected invention and/or species

2. The filing date of the instant claims is deemed to be the filing date of priority application USSN 09/446,083, filed 5/19/95.

3. Applicant should amend the first line of the specification to update the status of the priority documents.

4. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. Applicant should restrict the title to the claimed invention.

5. The application is required to be reviewed and all spelling, TRADEMARKS, and like errors corrected.

Trademarks should be capitalized or accompanied by the ™ or ® symbol wherever they appear and be accompanied by the generic terminology. Although the use of trademarks is permissible in patent applications, the proprietary nature of the trademarks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as trademarks.

Appropriate corrections are required

6. The following is a quotation of the first paragraph of 35 U.S.C. § 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claim 65 is rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention

In vitro and animal model studies have not correlated well with in vivo clinical trial results in patients. Since the therapeutic indices of immunosuppressive drugs or biopharmaceutical drugs can be species- and model-dependent, it is not clear that reliance on the various in vitro assays disclosed in the application as filed accurately reflects the relative ability of antibodies that bind MKK3 to inhibit "MKK-mediated disorders" as broadly encompassed by the claimed invention and as broadly disclosed in the specification (e.g., see page 10, paragraphs 1-3 of the instant specification), including autoimmune diseases such as rheumatoid arthritis encompassed by the claimed therapeutic strategies.

Pharmaceutical therapies in the absence of in vivo clinical data are unpredictable for the following reasons; (1) the protein may be inactivated before producing an effect, i.e. such as proteolytic degradation, immunological inactivation or due to an inherently short half-life of the protein; (2) the protein may not reach the target area because, i.e. the protein may not be able to cross the mucosa or the protein may be adsorbed by fluids, cells and tissues where the protein has no effect; and (3) other functional properties, known or unknown, may make the protein unsuitable for in vivo therapeutic use, i.e. such as adverse side effects prohibitive to the use of such treatment. See page 1338, footnote 7 of Ex parte Aggarwal, 23 USPQ2d 1334 (PTO Bd. Pat App. & Inter. 1992).

The specification does not adequately teach how to effectively treat any disorder or reach any therapeutic endpoint in humans by administering antibodies that bind MKK3. The specification does not teach how to extrapolate data obtained from in vitro assays determining kinase expression and activity to the development of effective in vivo human therapeutic methods to inhibit MKK-mediated disorders, commensurate in scope with the claimed invention. Therefore, it is not clear that the skilled artisan could predict the efficacy of antibodies that bind MKK3, in turn, would treat the variety of disorders and conditions, including rheumatoid arthritis.

Further, it is noted that experimental protocols usually are conducted under defined conditions wherein the antagonist and the stimulus/insult occur at the same or nearly the same time. Immunosuppression is much easier to achieve under such controlled conditions that experienced in the human immunoregulatory diseases such as autoimmunity targeted by the claimed invention. With respect to in vivo studies, animal models validate concepts based on studies of human disease, such studies are limited to the "acute" as opposed to "chronic" nature of the disease. In animal models, the onset of inflammation is rapid with an aggressive destructive process, whereas in humans the disease progresses more slowly, often with natural periods of disease exacerbation and remission.

The following is noted in determining the role of kinases, such as the MAP kinases, in signal transduction pathways and various pathophysiologic processes.

For example, Bokemeyer et al. (J Am Soc Nephrol 13: 1473-1480, 2002) reports that "Although an extensive body of data describes the pivotal role of ERK signaling pathway in the control of cellular proliferation in vitro, little is know regarding the roles of ERK1 and ERK2 in physiologic or pathophysiologic conditions or their activation in vivo" (page 1473, paragraph 1 of the Introduction). Furthermore, it is noted here that "the physiologic function of most of the growing group of MAP kinases, including stress-activated protein kinases even in vitro is less well defined". To indicate the importance for some objective evidence in determining the ability to inhibit a kinase in disorders, the Discussion discloses that "although our data suggested that ERK contributed to glomerular proliferation in vivo, no interventional studies were available that examined whether inhibition of ERK activation could prevent cellular proliferation in inflammatory diseases, especially with respect to the kidney" (page 1478, column 1). Bokemeyer et al. also concludes that "it is essential to establish the pathophysiologic relevance of the MEK-ERK module in each form of immune injury, to identify the diseases that are most likely to benefit from treatment with a MEK inhibitor" (see page 1479, column 2, paragraph 1 in the Discussion). "Such studies, other than this study, have not bee performed".

Wolf et al. (Israel Medical Association Journal 4: 641-647, 2002) address the ERK cascade in the pathogenesis of human diseases (see entire document, including page 644, column 2). For example, "laboratories have been trying to elucidate the role of the MAP kinase cascades and the ERK cascade in particular. Although the detection of ERK activation is fairly simple, interpretation of these studies mandates caution. One should bear in mind that the ERK cascade participates in various ways in many physiologic processes, thus making it hard to discern its exact role in disease states". Wolf et al. concludes that stating that: "Despite these encouraging developments, one must remember that since the activation of ERKs occur in so many physiologic processes, which obviously must not be inhibited, its inhibition in a non-specific manner might be harmful and thus prevent the clinical use of ERK cascade inhibitors" (see page 646, column 1, paragraph 2).

There appears to be insufficient evidence that applicant's reliance on the characterization of MKK3 would indicate that the claimed therapeutic modalities based upon anti-MMK3 antibody antagonists would be effective on either acute or chronic diseases, commensurate in scope with the claimed invention. Although a kinase may be involved in cell signaling pathways in normal and pathologic conditions, the ability of an antibody to such a kinase to lead some effective therapeutic endpoint will depend on the kinase, the antagonist and the particular nature of the disease (e.g. acute versus chronic). In humans, the claimed diseases encompassed by the claimed methods are already established before therapy is offered. There are distinct differences in the kinase requirements for particular types of inflammation.

There is insufficient objective evidence that the binding of a single compound such as an anti-MMK3 antibody to a kinase can be extrapolated to predict the efficacy of this anti-MMK3 antibody can inhibit or treat the variety of MKK3-mediated disorders, commensurate in scope with the claimed invention.

Given the relative incomplete understanding in the biotechnological field involved, and the lack of a reasonable correlation between the narrow disclosure in the specification and the broad scope of protection sought in the claims, a rejection under 35 USC 112, first paragraph for lack of enablement is appropriate. Also see MPEP 2164.08

In view of the lack of predictability of the art to which the invention pertains the lack of established clinical protocols for effective therapies for antibodies that inhibit kinases and, in turn, inhibit inflammatory conditions, including rheumatoid arthritis, undue experimentation would be required to practice the claimed methods with a reasonable expectation of success, absent a specific and detailed description in applicant's specification of how to effectively practice the claimed methods and absent working examples providing evidence which is reasonably predictive that the claimed methods are effective for inhibiting MKK3-mediated disorders broadly encompassed by the claimed invention.

7. Claim 65 is rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A) Claim 65 is indefinite in the recitation of "MKK-mediated disorder" because "MKK-mediated disorders" are not a recognized class of disorders by one of ordinary skill in the art. Further, the ordinary artisan would not recognize or acknowledge that the various MKK-mediated disorders disclosed in the specification as filed (e.g. autoimmune disorders such as arthritis or malignancy as disclosed on page 10, paragraphs 1-3 of the instant specification) are necessarily pathological conditions resulting from excessive activation of an MKK signal transduction pathway and, more particularly, resulting from excessive activation of an MKK3 signal transduction pathway.

B) Claim 65 is indefinite in the recitation of "modulates MKK activity" because the claims fails to state the function which is to be achieved. The phrase "modulates MKK activity" is relative in nature, which renders the claims indefinite. The phrase "modulates MKK activity" is not defined by the claims; the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the metes and bounds of the invention

C) Applicant is reminded that the amendment must point to a basis in the specification so as not to add any new matter. See MPEP 714.02 and 2163.06

Applicant is invited to consider reciting an endpoint(s) in clear and positive terms.

8. Claim 65 is objected to because the recitation of the abbreviation"MKK" should be spelled out upon first time usage for clarity.

9. No claim is allowed.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (571) 272-0844. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 872-9306.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Phillip Gambel, PhD.
Primary Examiner
Technology Center 1600
January 22, 2004